The Potentiation Activity of Azithromycin in Combination with Colistin or Levofloxacin Against Pseudomonas aeruginosa Biofilm Infection

References

• Litwin A, Rojek S, Gozdzik W, Duszynska W. Pseudomonas aeruginosa device associated - healthcare associated infections and its multidrug resistance at intensive care unit of university hospital: polish, 8.5-year, prospective, single-centre study. BMC Infect Dis. 2021;21:180. doi:10.1186/s12879-021-05883-5
   PubMed Web of Science ®Google Scholar
• Ghssein G, Ezzeddine Z. Pseudomonas aeruginosa review of metallophores: pyoverdine, pyochelin and pseudopaline. Biology. 2022;2022:11.
   Google Scholar
• Blanco-Cabra N, Paetzold B, Ferrar T, et al. Characterization of different alginate lyases for dissolving pseudomonas aeruginosa biofilms. Sci Rep. 2020;10:9390. doi:10.1038/s41598-020-66293-2
   PubMed Web of Science ®Google Scholar
• Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl. 2013;121(s136):1–51. doi:10.1111/apm.12099
   Google Scholar
• Olivares E, Badel-Berchoux S, Provot C, Prévost G, Bernardi T, Jehl F. Pseudomonas aeruginosa clinical impact of antibiotics for the treatment of biofilm infections. Front Microbiol. 2019;10:2894. doi:10.3389/fmicb.2019.02894
   PubMedGoogle Scholar
• Seebach E, Kubatzky K. Chronic implant-related bone infections-can immune modulation be a therapeutic strategy? Front Immunol. 2019;10:1724. doi:10.3389/fimmu.2019.01724
   PubMed Web of Science ®Google Scholar
• Jalil A, Alrawe R, Al-Saffar M, et al. The use of combination therapy for the improvement of colistin activity against bacterial biofilm. Braz J Microbiol. 2023;55(1):411–427. doi:10.1007/s42770-023-01189-7
   PubMedGoogle Scholar
• Martin I, Waters V, Grasemann H, Romero MP. Approaches to targeting bacterial biofilms in cystic fibrosis airways. Int J Mol Sci. 2021;23(1):22. doi:10.3390/ijms23010022
   PubMedGoogle Scholar
• Pons S, Arrii E, Arnaud M, et al. Immunomodulation of endothelial cells induced by macrolide therapy in a model of septic stimulation. Immun inflam dis. 2021;9(4):1656–1669. doi:10.1002/iid3.518
   PubMedGoogle Scholar
• Polancec D, Munic Kos V, Banjanac M, et al. Azithromycin drives in vitro GM-CSF/IL-4-induced differentiation of human blood monocytes toward dendritic-like cells with regulatory properties. J Leukoc Biol. 2012;91(2):229–243. doi:10.1189/jlb.1210655
   PubMed Web of Science ®Google Scholar
• Parnham M, Erakovic Haber V, Giamarellos-Bourboulis E, Perletti G, Verleden G, Vos R. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther. 2014;143(2):225–245. doi:10.1016/j.pharmthera.2014.03.003
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Acinetobacter baumannii A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant in Critically Ill Patients: A Propensity Score-Matched Analysis. Antibiotics. (Basel, Switzerland):MDPI; 2020:9.
   Google Scholar
• Wang X, Cai Y, Xing H, et al. Increased therapeutic efficacy of combination of azithromycin and ceftazidime on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection. BMC Microbiol. 2016;16:124. doi:10.1186/s12866-016-0744-1
   PubMedGoogle Scholar
• Wang Y, Li C, Wang J, et al. The efficacy of colistin combined with amikacin or levofloxacin against pseudomonas aeruginosa biofilm infection. Microbiol Spectr. 2022;10(5):e0146822. doi:10.1128/spectrum.01468-22
   PubMedGoogle Scholar
• Weinstein MP, Bobenchik IIJSL, Campeaus AM. Performance standards for antimicrobial susceptibility testing. Clinical Lab Stand Inst. 2020;2020:M100.
   Google Scholar
• Chai D, Liu X, Wang R, Bai Y, Cai Y. Efficacy of linezolid and fosfomycin in catheter-related biofilm infection caused by methicillin-resistant staphylococcus aureus. Biomed Res Int. 2016;2016:6413982. doi:10.1155/2016/6413982
   PubMed Web of Science ®Google Scholar
• Poulakou G, Renieris G, Sabrakos L, et al. Daptomycin as adjunctive treatment for experimental infection by Acinetobacter baumannii with resistance to colistin. Int J Antimicrob Agents. 2019;53:190–194. doi:10.1016/j.ijantimicag.2018.10.024
   PubMed Web of Science ®Google Scholar
• FDA. Approved Drug Product LEVAQUIN; 2024. Available from: https://wwwaccessdatafdagov/drugsatfda_docs/label/2020/020634s073lblpdf.Accessed March 20,2024.
   Google Scholar
• SmPC. Amikacin summary of product characteristics (SmPC); 2020.
   Google Scholar
• FDA. Approved drug product for zithromax. 2024. Available from: https://s3-us-west-2amazonawscom/drugbank/cite_this/attachments/files/000/003/154/original/zithromax_fdapdf?1548452062.Accessed March 20,2024.
   Google Scholar
• Krespi Y, Kizhner V, Nistico L, Hall-Stoodley L, Stoodley P. Laser disruption and killing of methicillin-resistant Staphylococcus aureus biofilms. Am J Otolaryngol. 2011;32:198–202. doi:10.1016/j.amjoto.2010.01.010
   PubMed Web of Science ®Google Scholar
• Xiong Y, Willard J, Kadurugamuwa J, Yu J, Francis K, Bayer A. Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat staphylococcus aureus endocarditis Model. Antimicrob Agents Chemother. 2005;49(1):380–387. doi:10.1128/AAC.49.1.380-387.2005
   PubMed Web of Science ®Google Scholar
• Roudashti S, Zeighami H, Mirshahabi H, Bahari S, Soltani A, Haghi F. Synergistic activity of sub-inhibitory concentrations of curcumin with ceftazidime and ciprofloxacin against Pseudomonas aeruginosa quorum sensing related genes and virulence traits. World J Microbiol Biotechnol. 2017;33(3):50. doi:10.1007/s11274-016-2195-0
   PubMed Web of Science ®Google Scholar
• Cirioni O, Ghiselli R, Silvestri C, et al. Effect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection. J Antimicrob Chemother. 2011;66:1318–1323. doi:10.1093/jac/dkr107
   PubMed Web of Science ®Google Scholar
• Yang Y, Guo Y, Yin D, et al. In vitro activity of cefepime-zidebactam, ceftazidime-avibactam, and other comparators against clinical isolates of, pseudomonas aeruginosa, and Acinetobacter baumannii: results from china antimicrobial surveillance network (CHINET) in 2018. Antimicrob Agents Chemother. 2020;2020:65.
   Google Scholar
• Herrmann G, Yang L, Wu H, et al. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm pseudomonas aeruginosa. J Infect Dis. 2010;202:1585–1592. doi:10.1086/656788
   PubMed Web of Science ®Google Scholar
• Pang Z, Raudonis R, Glick B, Lin T, Cheng Z. Antibiotic resistance in pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37:177–192. doi:10.1016/j.biotechadv.2018.11.013
   PubMed Web of Science ®Google Scholar
• Bulman Z, Ly N, Lenhard J, Holden P, Bulitta J, Tsuji B. rhlR influence of and on polymyxin pharmacodynamics in pseudomonas aeruginosa and implications for quorum sensing inhibition with azithromycin. Antimicrob Agents Chemother. 2017;2017:61.
   Google Scholar
• Katip W, Oberdorfer P, Kasatpibal N, Singhvi G. Acinetobacter baumanniiEffectiveness and nephrotoxicity of loading dose colistin-meropenem versus loading dose colistin-imipenem in the treatment of carbapenem-resistant Infection. Pharmaceutics. 2022;15(1):14. doi:10.3390/pharmaceutics15010014
   PubMedGoogle Scholar
• Yassien M, Khardori N. Interaction between biofilms formed by Staphylococcus epidermidis and quinolones. Diagn Microbiol Infect Dis. 2001;40(3):79–89. doi:10.1016/S0732-8893(01)00253-X
   PubMedGoogle Scholar
• Drago L, Mattina R, Legnani D, et al. Modulation of biofilm of strains isolated from patients with chronic obstructive pulmonary disease by levofloxacin, moxifloxacin, ciprofloxacin, amoxicillin/clavulanic acid and ceftriaxone. Int J Immunopathol Pharmacol. 2011;24(4):1027–1035. doi:10.1177/039463201102400420
   PubMedGoogle Scholar
• Eng R, Padberg F, Smith S, Tan E, Cherubin C. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob Agents Chemother. 1991;35(9):1824–1828. doi:10.1128/AAC.35.9.1824
   PubMed Web of Science ®Google Scholar
• Goto T, Nakame Y, Nishida M, Ohi Y. In vitro bactericidal activities of beta-lactamases, amikacin, and fluoroquinolones against Pseudomonas aeruginosa biofilm in artificial urine. Urology. 1999;53(5):1058–1062. doi:10.1016/S0090-4295(98)00649-9
   PubMedGoogle Scholar
• Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother. 2008;61(4):859–868. doi:10.1093/jac/dkn059
   PubMed Web of Science ®Google Scholar
• Saiman L, Marshall B, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749–1756. doi:10.1001/jama.290.13.1749
   PubMed Web of Science ®Google Scholar
• Ezzeddine Z, Ghssein G. Towards new antibiotics classes targeting bacterial metallophores. Microb Pathog. 2023;182:106221. doi:10.1016/j.micpath.2023.106221
   PubMed Web of Science ®Google Scholar